Novo Nordisk A/S pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic.
Bloomberg - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Company
Trending
Categories
© Bloombergnews. All rights resereved